Study [references] |
Duration study conducted |
Radiation
techniques |
Sample size
(n) |
Follow up period |
Locoregional Control |
Freedom From Distant metastasis |
Overall survival |
Kim TH [4] |
1981-1997 |
3DCRT |
23 |
7 years |
95.2% |
NA |
90% |
Chen PV [5] |
1973-2001 |
Conventional;3DCRT |
44 |
7.8 years |
93% |
NA |
90% |
Tubiana M [6] |
1943-1965 |
conventional |
55 |
5 years |
NA |
53% |
60.6% |
MSDS trial [12] |
2003-2004 |
3DCRT |
26 |
2.5 years |
97% |
NA |
96% |
Terezakis SA [13] |
1989-2006 |
3DCRT |
76 |
4 years |
72% |
NA |
55% |
Azrif M [14] |
1990-2000 |
Conventional
3DCRT |
49 |
5.4 years |
81.4% |
|
75.7% |
Keum KC [15] |
1990-2005 |
Conventional;3DCRT |
25 |
10 years |
89% |
NA |
NA |
Meadows KM [16] |
1999-2000 |
3DCRT |
42 |
5 years |
89% |
60% |
60% |
Ford D [17] |
1988-2001 |
Conventional;3DCRT |
41 |
5 years |
74% |
NA |
67% |
Busutti L [18] |
1982-1995 |
Conventional;3DCRT |
243 |
5 years |
93.7% |
93.7% |
93.7% |
O'Connel ME [19] |
1969-1991 |
conventional |
103 |
4 years |
81% |
NA |
27%-85% |
Kim JH [20] |
1979-1986 |
Conventional with doxorubicin |
22 |
2 years |
77% |
NA |
NA |
Brierly J [21] |
1958-1998 |
conventional |
70 |
10 years |
84.9% |
87.3% |
65.7% |
3DCRT= Three dimensional conformal Radiation therapy, NA= not available |